Business Wire

Tigo Energy Delivers Scalable Insights on EI Platform for High-Growth, Multi-Site Solar Installers

9.7.2024 16:00:00 EEST | Business Wire | Press release

Share

Tigo Energy, Inc. (NASDAQ: TYGO), a leading provider of intelligent solar and energy software solutions, today unveiled a new set of powerful and customizable features of the Tigo Energy Intelligence (EI) Platform. With a newly retooled, upgraded, and tiered approach to delivering the right solar monitoring and insights, even small and mid-sized installation companies can manage their growing solar customer portfolios sustainably. These platform enhancements come online as the U.S. installed base of solar surpasses the 5 million solar installations threshold and the industry considers how it will manage the O&M work as those numbers double by 2030 and triple by 2034.

The Tigo EI Platform now offers upgrade options that deliver even more of the right information at the right time via a user-friendly interface to installers, asset managers, and down to the individual system owner. Most notably for rapidly scaling installers, EPCs, and O&M providers, the new EI Professional package provides a centralized view of critical health and performance data of all systems under management. Beyond a scalable monitoring experience and a simple, flat-price model, the EI Professional package includes:

  • one-click enrollment for company-wide, unlimited-seat subscription access covering all systems under management,
  • a portfolio-wide dashboard with a prioritized view into critical data, such as health status, production, performance, equipment status, location data, and commissioning time tracking, and
  • time-saving features including advanced tagging, grouping, and site filtering for improved management, maintenance, optimization, and trend analysis.

Solar installers use the Tigo EI Platform to gain improved insights into installation status, decrease O&M costs, and monitor energy generation and system performance. The standard system-by-system monitoring view, now named EI Basic, remains free of charge, and includes module-level resolution and insight into third-party hardware. More advanced monitoring and analytics tools, historical data, and minute-level monitoring resolution, among others, are available via a simple, in-platform upgrade to EI Premium.

“As we watch the number, size, and complexity of the residential and commercial systems we deploy increase, we found that the only way to scale was with a comprehensive way to monitor, diagnose, and optimize those systems,” said Garrett Brandt, owner at Radius Energy. “When you consider the cost of even a single truck roll or the opportunity cost of a one-week delay in getting an invoice out post-commissioning, a paid subscription to avoid either makes sense right away. The features now available via the Tigo EI Platform don’t just add value in terms of savings but represent new opportunities for us on the installer side.”

Installer training materials for the EI Platformare now available in the Tigo Academy. Tigo Academy offers new and existing customers and installers an efficient way to learn about Tigo software through hands-on demonstrations and tutorials on how to leverage Tigo software for optimal system performance and customer satisfaction.

“To stay competitive, installers have to become more agile while providing more post-installation services, which is why Tigo has developed increasingly sophisticated options in the EI Platform that deliver the right management tools to the variety of customers we serve,” said Archie Roboostoff, vice president of software, at Tigo Energy. “Software plays an increasingly important role in ensuring that solar deployments reach peak performance while continuously analyzing trends to see where improvements can be made. The EI Platform is designed to identify system issues before production is impacted. System owners expect quality and reliability, and the EI Platform helps to deliver both.”

To learn more about the Tigo EI Platform, including the standard capabilities of EI Basic and the features and subscription pricing for EI Premium and EI Professional, please visit the EI features page at https://www.tigoenergy.com/ei/pricing. Tigo installers are also invited to take advantage of promotional trial access to EI Professional for the month of July, which is available via web browser on the Tigo EI Platform: https://ei.tigoenergy.com/

About Tigo Energy

Founded in 2007, Tigo is a worldwide leader in the development and manufacture of smart hardware and software solutions that enhance safety, increase energy yield, and lower operating costs of residential, commercial, and utility-scale solar systems. Tigo combines its Flex MLPE (Module Level Power Electronics) and solar optimizer technology with intelligent, cloud-based software capabilities for advanced energy monitoring and control. Tigo MLPE products maximize performance, enable real-time energy monitoring, and provide code-required rapid shutdown at the module level. The company also develops and manufactures products such as inverters and battery storage systems for the residential solar-plus-storage market. For more information, please visit www.tigoenergy.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240709862359/en/

Contacts

Technica Communications
Cait Caviness
Email: tigoenergy@technica.inc -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Ftigoenergy%40te
chnica.inc&esheet=54092036&newsitemid=20240709862359&lan=en-US&anchor=tigoenergy
%40technica.inc&index=8&md5=f7a31dc632c64a578651acfbf13ae9c6

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Azafaros to Present at BIO International Convention 202615.6.2026 08:00:00 EEST | Press release

Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A

Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 07:05:00 EEST | Press release

Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye